Elevation Oncology Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Elevation Oncology Inc (ELEV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Elevation Oncology Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Elevation Oncology inc | - | - | - | Yes |
| Competitors combined (16) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ELEV Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 2 | Inhibrx Biosciences Inc | 282.9% | Outperformed |
| 3 | Zymeworks Inc | 282.9% | Outperformed |
| 4 | C4 Therapeutics Inc | 282.9% | Outperformed |
| 5 | Scholar Rock Holding Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Elevation Oncology Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Elevation Oncology Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Elevation Oncology inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Elevation Oncology inc | 21.60 | - |
| Argenx Se | 54,087.17 | 8,399.37 |
| Blueprint Medicines Corporation | 8,615.12 | 562.12 |
| Scholar Rock Holding Corp | 5,211.45 | 47.30 |
| Crispr Therapeutics Ag | 4,753.32 | 13.39 |
| Relay Therapeutics Inc | 3,302.39 | 0.70 |
| SUBTOTAL | 82,498.14 | 10,308.12 |
Sign in to see all competitors of Elevation Oncology inc .
Sources: Elevation Oncology inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Elevation Oncology inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Elevation Oncology Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Biocryst Pharmaceuticals Inc | Reportable 100.00 % |
| Editas Medicine Inc | Reportable 100.00 % |
| Black Diamond Therapeutics Inc | Reportable 100.00 % |
| Sangamo Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Elevation Oncology Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Elevation Oncology inc | 22 | - | -571,298 |
| Argenx Se | 54,087 | 7,316,521 | 1,125,466 |
| Blueprint Medicines Corporation | 8,615 | 965,844 | -267,576 |
| Scholar Rock Holding Corp | 5,211 | 163,671 | -1,413,810 |
| Crispr Therapeutics Ag | 4,753 | 66,627 | -2,244,473 |
| Relay Therapeutics Inc | 3,302 | 3,620 | -1,489,776 |
| PEERS TOTAL | 82,477 | 2,577,675 | -330,379 |
Sign in to see all peers for Elevation Oncology inc .
Elevation Oncology Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Elevation Oncology Inc's industry classification, broader than the peer set above. Market cap in millions of $.Elevation Oncology Inc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,352, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 235,275 | 26.26 % |
| 2 | Gilead Sciences Inc | 194,144 | 21.67 % |
| 3 | Moderna Inc | 86,768 | 9.69 % |
| 4 | Argenx Se | 54,087 | 6.04 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Elevation Oncology inc | 22 | 0.00 % |
Market cap and industry share for the rest of Elevation Oncology Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-07-22.
Elevation Oncology Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 22.7x | - |
| EV / EBITDA | - | 17.6x | - |
| P/B | 0.5x | 5.0x | -4.5x |
| Return on Equity | -74.68 % | industry aggregate | -82.35 % |
| Return on Invested Capital | -30.73 % | -5.14 % (avg) | -25.59 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Elevation Oncology Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -50.55 % | -32.13 % | -25.69 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Elevation Oncology Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,352 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Elevation Oncology Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Elevation Oncology Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Elevation Oncology Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 82.4 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (40.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-80.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Elevation Oncology Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Elevation Oncology inc | 12.51 | 22.76 | 0.48 |
| Argenx Se | 2.64 | 5.23 | - |
| Blueprint Medicines Corporation | 0.36 | 3.16 | 2.48 |
| Scholar Rock Holding Corp | 5.93 | 7.21 | 0.58 |
| Crispr Therapeutics Ag | 2.51 | 16.26 | 0.16 |
| Relay Therapeutics Inc | 3.61 | 20.10 | - |
Sign in to see all peers for Elevation Oncology inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Elevation Oncology Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Elevation Oncology inc | Q1 2025 | - | - |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Blueprint Medicines Corporation | Q1 2025 | +55.5 % | -99.4 % |
| Scholar Rock Holding Corp | Q2 2026 | - | - |
| Crispr Therapeutics Ag | Q2 2026 | +1,041.4 % | - |
| Relay Therapeutics Inc | Q2 2026 | -48.3 % | - |
| PEERS TOTAL | +85.4 % | +213.6 % |
Sign in to see all peers for Elevation Oncology inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Elevation Oncology Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Elevation Oncology inc | Q1 2025 | - | - |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Blueprint Medicines Corporation | Q1 2025 | -12.2 % | +65.9 % |
| Scholar Rock Holding Corp | Q2 2026 | - | -99.5 % |
| Crispr Therapeutics Ag | Q2 2026 | - | +453.8 % |
| Relay Therapeutics Inc | Q2 2026 | - | - |
Sign in to see all peers for Elevation Oncology inc .
Elevation Oncology Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Elevation Oncology inc | - | - | - |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Blueprint Medicines Corporation | - | - | - |
| Scholar Rock Holding Corp | - | - | - |
| Crispr Therapeutics Ag | - | - | - |
| Relay Therapeutics Inc | - | - | - |
Sign in to see all peers for Elevation Oncology inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Elevation Oncology Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Elevation Oncology inc | - | - |
| Argenx Se | 41.86 | 6.44 |
| Blueprint Medicines Corporation | - | 15.33 |
| Scholar Rock Holding Corp | - | 110.18 |
| Crispr Therapeutics Ag | - | 354.94 |
| Relay Therapeutics Inc | - | 4,751.64 |
| PEERS AVERAGE | - | 8.00 |
Sign in to see all peers for Elevation Oncology inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.